


10/520580
REPLACED BY
ART. 34 AMDT

Claims

1. Use of a simmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or mixtures thereof for the manufacture of a medicament for inhibiting angiogenesis.
2. Use according to claim 1, whereby said simmondsin naturally occurs in jojoba and is comprised within jojoba flour or a jojoba extract.
3. Use according to claim 1 or 2, whereby said simmondsin is selected from the group comprising 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4,5-dimethylsimmondsin, stereoisomeric forms, racemic mixtures, metabolites, esters or salts thereof, or any mixtures thereof.
4. Use according to any of claims 1-3 wherein said esters are ferulates.
5. Use according to any of claims 1-4, whereby said simmondsin is selected from the group comprising 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, 4,5-didesmethylsimmondsin-2'-ferulate, 4,5-dimethylsimmondsin-2'-ferulate, and any mixtures thereof.
6. Use of a compound having general formula (I)



Formula (I)

and stereoisomeric forms, racemic mixtures, metabolites, esters, salts, or mixtures thereof, for the manufacture of a medicament for inhibiting angiogenesis,

wherein R_4 and R_5 are independently selected from the group comprising oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkyloxycarbonyl, alkylthiocarbonyl, alkanoyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkanoyl, cycloalkylthiocarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkoxythiocarbonyl, cycloalkylthioalkyl, alkylcarbonyloxyalkyl,

arylcarbonyloxyalkyl, cycloalkylcarbonyloxyalkyl, silyloxyalkyl, aryl, aralkyl, arylalkenyl, arylcarbonyl, aryloxycarbonyl, arylthiocarbonyl, aralkoxycarbonyl, arylalkylthiocarbonyl, aryloxyalkyl, arylthioalkyl, haloalkyl, hydroxyalkyl, aralkanoyl, aroyl, aryloxycarbonylalkyl, aryoxyalkanoyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl, cyano, aminocarbonyl, aminoalkanoyl, aminoalkyl, $CR^6=NR^7$ or $CR^6=N(OR^7)$, with R^6 and R^7 being independently selected from the group comprising hydrogen, hydroxyl, alkyl, aryl, alkenyl, alkynyl, aminoalkyl, aminoaryl, alkylcarbonylamino, arylcarbonylamino, alkylthiocarbonylamino and arylthiocarbonylamino; and

wherein R_3 , R_2 , R_3 , R_4 , and R_6 are independently selected from the group comprising hydroxyl or an ester.

7. Use of a compound having general formula (I) according to claim 6, wherein R_4 and R_5 are independently selected from the group comprising oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkyloxycarbonyl, alkylthiocarbonyl, alkanoyl, lkyloxyalkyl, arylcarbonyloxyalkyl, silyloxyalkyl, haloalkyl, hydroxyalkyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl, cyano, aminocarbonyl, aminoalkanoyl, aminoalkyl, and wherein R_3 , R_2 , R_3 , R_4 , and R_6 are independently selected from the group comprising hydroxyl or an ester.

8. Use of a compound having general formula (I) according to claim 6 or 7, wherein R_4 and R_5 are independently selected from the group comprising hydroxyl, alkyl, alkyloxy, and wherein R_3 , R_2 , R_3 , R_4 , and R_6 are independently selected from the group comprising hydroxyl or an ester.

9. Use of a compound having general formula (I) according to any of claims 6-8, wherein R_4 and R_5 are independently selected from the group comprising hydroxyl, and $-OCH_3$, and wherein R_3 , R_2 , R_3 , R_4 , and R_6 are independently selected from the group comprising hydroxyl or an ester.

10. Use of a compound having general formula (I) according to any of claims 6-9, wherein said ester is a ferulate.

11. A simmondsin having general formula (I), as defined in claim 6, for use as a medicament.

12. Jojoba flour or an extract from jojoba for use as a medicament.

**REPLACED BY
ART 34 AMDT**

13. A compound having general formula (I) as defined in claim 6.

14. A pharmaceutical composition comprising a therapeutically effective amount of a
5 compound as defined in claim 6 and a pharmaceutically acceptable excipient.

15. Pharmaceutical composition according to claim 14, wherein said pharmaceutical
composition is formulated to be applied orally.

10 16. Pharmaceutical composition according to claim 14, wherein said pharmaceutical
composition is formulated to be applied parentally.

17. Pharmaceutical composition according to claim 14, wherein said pharmaceutical
composition is formulated to be applied topically.

15

18. Method of inhibiting angiogenesis in humans and animals comprising administering to
the human or animal in need thereof a therapeutically effective amount of a compound as
defined in claim 6.

20